PURPOSE: The aim of this project was to review the literature and define clinical practice guidelines for the use of cytokines and growth factor agents for the prevention or treatment of oral mucositis induced by cancer chemotherapy or radiotherapy. METHODS: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, No guideline possible. RESULTS: Sixty-four clinical studies across 11 interventions were evaluated. A recommendation was made for the use of recombinant human KGF-1 (palifermin) at a dose of 60 μg/kg per day for 3 days prior to conditioning treatment and for 3 days post-transplant for prevention of oral mucositis in patients receiving high-dose chemotherapy and total body irradiation followed by autologous stem cell transplantation for hematological malignancies. A suggestion was made against using granulocyte macrophage colony-stimulating factor mouthwash for the prevention of oral mucositis in the setting of high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation. No guideline was possible for any other cytokine or growth factor agents due to inconclusive evidence. CONCLUSIONS: Of the cytokine and growth factor agents studied for oral mucositis, the evidence only supports use of palifermin in the specific population listed above. Additional well-designed research is needed on other cytokine and growth factor interventions and in other cancer treatment settings.
PURPOSE: The aim of this project was to review the literature and define clinical practice guidelines for the use of cytokines and growth factor agents for the prevention or treatment of oral mucositis induced by cancer chemotherapy or radiotherapy. METHODS: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, No guideline possible. RESULTS: Sixty-four clinical studies across 11 interventions were evaluated. A recommendation was made for the use of recombinant human KGF-1 (palifermin) at a dose of 60 μg/kg per day for 3 days prior to conditioning treatment and for 3 days post-transplant for prevention of oral mucositis in patients receiving high-dose chemotherapy and total body irradiation followed by autologous stem cell transplantation for hematological malignancies. A suggestion was made against using granulocyte macrophage colony-stimulating factor mouthwash for the prevention of oral mucositis in the setting of high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation. No guideline was possible for any other cytokine or growth factor agents due to inconclusive evidence. CONCLUSIONS: Of the cytokine and growth factor agents studied for oral mucositis, the evidence only supports use of palifermin in the specific population listed above. Additional well-designed research is needed on other cytokine and growth factor interventions and in other cancer treatment settings.
Authors: Cesar O Freytes; Voravit Ratanatharathorn; Charles Taylor; Camille Abboud; Nancy Chesser; Alejandro Restrepo; Jorge Arango; Daniel Odenheimer Journal: Clin Cancer Res Date: 2004-12-15 Impact factor: 12.531
Authors: A A Abitbol; K S Sridhar; A A Lewin; J G Schwade; W Raub; A Wolfson; C Gonzalez-Angulo; A Adessa; W J Goodwin; A M Markoe Journal: Cancer Date: 1997-07-15 Impact factor: 6.860
Authors: C Dazzi; A Cariello; P Giovanis; M Monti; B Vertogen; M Leoni; A Tienghi; D Turci; G Rosti; O Nanni; C Rondoni; M Marangolo Journal: Ann Oncol Date: 2003-04 Impact factor: 32.976
Authors: L Cartee; W P Petros; G L Rosner; C Gilbert; S Moore; M L Affronti; J A Hoke; A M Hussein; M Ross; P Rubin Journal: Cytokine Date: 1995-07 Impact factor: 3.861
Authors: Philip Riley; Anne-Marie Glenny; Helen V Worthington; Anne Littlewood; Luisa M Fernandez Mauleffinch; Jan E Clarkson; Martin G McCabe Journal: Cochrane Database Syst Rev Date: 2017-11-28
Authors: Ana Gabriela Costa Normando; Camila Lopes Rocha; Isabela Porto de Toledo; Paulo Tadeu de Souza Figueiredo; Paula Elaine Diniz Dos Reis; Graziela De Luca Canto; Eliete Neves Silva Guerra Journal: Support Care Cancer Date: 2017-06-16 Impact factor: 3.603
Authors: Tine De Ryck; Annouchka Van Impe; Barbara W Vanhoecke; Arne Heyerick; Luc Vakaet; Wilfried De Neve; Doreen Müller; Margret Schmidt; Wolfgang Dörr; Marc E Bracke Journal: Strahlenther Onkol Date: 2014-11-29 Impact factor: 3.621
Authors: Ysabella Z A Van Sebille; Romany Stansborough; Hannah R Wardill; Emma Bateman; Rachel J Gibson; Dorothy M Keefe Journal: Curr Oncol Rep Date: 2015-11 Impact factor: 5.075